ClinicalTrials.gg
CompletedNCT03037515Updated Nov 10, 2026Results posted

Oral and Intravenous Tranexamic Acid in Lumbar Spine Surgery

A Phase 4 interventional study of Tranexamic Acid in Blood Loss, Surgical and Blood Loss Anemia, sponsored by Henry Ford Health System. Completed at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by Henry Ford Health System · Phase 4, Interventional, and Prevention

How we know

Updated Nov 10, 2026Results postedStudy documents posted+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
83
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 46 studies testing Tranexamic Acid in Blood Loss, Surgical — 9 open to participants now, 9 under way, 4 of them phase 3. Tranexamic Acid · Blood Loss, Surgical.

Enrollment
30th of 46
83 · median 98
Started
2017
with 3 others
Phase 4
18 of 46
1 open now
Registered
13th of 46
by date

Among the 46 studies testing Tranexamic Acid in Blood Loss, Surgical, this one is the 30th largest by enrollment, is one of 4 that started in 2017, is one of 18 in phase 4, and was the 13th registered.

Blood Loss, Surgical

213 studies on the registry are indexed under Blood Loss, Surgical; 40 are open to participants now.

Browse Blood Loss, Surgical studies →

Open to participants now

9 of the 46 studies testing Tranexamic Acid in Blood Loss, Surgical are open now, in 6 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About Tranexamic Acid

Tranexamic Acid: first FDA approval 1986 (CYKLOKAPRON). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 27 Blood Loss, Surgical studies recruiting now, 10 (37%) set no upper age limit and 14 (52%) stop at 75 or younger; 6 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 46 studies testing Tranexamic Acid in Blood Loss, Surgical, or all of them as a file.
02

Study summary

The purpose of this project is to compare the effectiveness of two different but well accepted routes of administration of tranexamic acid in order to reduce blood loss and need for transfusion in patients undergoing lumbar spine surgery. Specifically, this study seeks to identify if intravenous tranexamic acid is superior to oral tranexamic acid in reducing blood loss and need for transfusion.

Read the detailed description

Spine surgery is associated with large amount of perioperative blood loss. Factors influencing blood loss include surgical technique, operative time, number of vertebral levels arthrodesed, and others. Significant blood loss is associated with complications such as hypotension, end organ damage, or coagulopathy. Blood transfusions can increase risks of infection, blood incompatibility, and allergic reactions. Due to the significant risks and complications associated with blood loss and allogenic transfusions, efforts to identify safe and effective ways of lowering blood loss during spine surgery are crucial. Many methods have been utilized to reduce allogenic blood transfusions, such as autologous blood predonation, antifibrinolytic drugs, acute normovolemic hemodilution, intraoperative blood salvage, and others. Furthermore, the administration of antifibrinolytics, such as tranexamic acid (TXA) and epsilon-aminocaproic acid (EACA), has been shown to reduce bleeding in cardiac, gynecological, urologic and total joint replacement surgeries. There have been many published studies investigating various antifibrinolytic agents such as TXA, EACA, and aprotinin. While aprotinin was shown to increase mortality rate in patients following cardiac surgery, TXA and EACA have not been shown to cause any substantial morbidity or to increase rate of thromboembolic events. Although IV TXA has been shown to be effective in reducing blood loss and transfusions in patients undergoing spine surgery, no studies in the literature have investigated the efficacy of PO TXA in decreasing blood loss and transfusions. The investigators believe that PO TXA will be just as efficacious and more cost-effective in reducing blood loss and transfusion needs in patients undergoing lumbar spine surgery.

The ultimate goal is identifying the most cost-effective protocol to decrease blood loss and need for transfusion. If oral TXA is found to be as efficacious as IV TXA in reducing blood loss and need for transfusion, significant cost savings can be achieved for the patient and the health care system in general.

03

Conditions studied

  • Blood Loss, Surgical
  • Blood Loss Anemia

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients over age 18 and scheduled for open lumbar spine surgery (primary or revision)
  • Must be able to swallow tablets

Exclusion criteria

Exclusion Criteria

  • Known allergy to TXA
  • History of renal failure or kidney transplant
  • History of arterial thromboembolic event (eg. myocardial infarction, stroke) within the past year
  • Placement of an arterial stent within the past year
  • History of blood clots (DVT, PE) within the past year
  • Refusal to receive blood products
05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
83 participants (actual)

Study arms

  • Active comparator
    Intravenous Tranexamic Acid

    The IV TXA group will receive the standard dosing for our institution of 1 g TXA (diluted in 100 mL normal saline) given as an IV bolus immediately before incision and another 1 g TXA given before closure.

    Drug: Tranexamic Acid

  • Active comparator
    Oral Tranexamic Acid

    The oral TXA group will receive 1950 mg TXA (3 tablets of 650 mg) approximately 2 hours before incision.

    Drug: Tranexamic Acid

Interventions

  • To identify if intravenous tranexamic acid is superior to oral tranexamic acid in reducing blood loss and need for transfusion in lumbar spine surgery.

    Also known as: Lysteda

06

What researchers measure

Primary outcomes

  1. Post-operative Change in Hemoglobin Level Between the Two Groups

    Time frame: Day of surgery up to 24 hours day after surgery

Secondary outcomes

  1. Post-operative Change of Blood Volume in Milliliters Between the Two Groups

    The total blood volume change is calculated in milliliters

    Time frame: 1 day after surgery until 7 days after surgery

  2. Number of Participants Transfused Between the Two Groups

    Time frame: 1 day after surgery until patient is discharged, up to 7 days

  3. Number of Participants Experiencing a Thromboembolic Event Between the Two Groups

    Time frame: 1 day after surgery until post operative visit 4 weeks after surgery

07

Results

Posted Nov 10, 2026

Participant flow

Participant flow — Overall Study
MilestoneIntravenous Tranexamic AcidOral Tranexamic Acid
Started4340
Completed4340
Not completed00

Outcome measures

PrimaryPost-operative Change in Hemoglobin Level Between the Two Groups
Time frame:
Day of surgery up to 24 hours day after surgery
Reported as:
Mean · grams per deciliter
Post-operative Change in Hemoglobin Level Between the Two Groups
grams per deciliterIntravenous Tranexamic AcidOral Tranexamic Acid
Post-operative Change in Hemoglobin Level Between the Two Groups3.36 (3 to 4)3.43 (3 to 4)
SecondaryPost-operative Change of Blood Volume in Milliliters Between the Two Groups

The total blood volume change is calculated in milliliters

Time frame:
1 day after surgery until 7 days after surgery
Reported as:
Mean · milliliters (mL)
Post-operative Change of Blood Volume in Milliliters Between the Two Groups
milliliters (mL)Intravenous Tranexamic AcidOral Tranexamic Acid
Post-operative Change of Blood Volume in Milliliters Between the Two Groups1235 (500 to 1420)1312 (480 to 1320)
SecondaryNumber of Participants Transfused Between the Two Groups
Time frame:
1 day after surgery until patient is discharged, up to 7 days
Reported as:
Count of participants · Participants
Number of Participants Transfused Between the Two Groups
ParticipantsIntravenous Tranexamic AcidOral Tranexamic Acid
Number of Participants Transfused Between the Two Groups2110
SecondaryNumber of Participants Experiencing a Thromboembolic Event Between the Two Groups
Time frame:
1 day after surgery until post operative visit 4 weeks after surgery
Reported as:
Count of participants · Participants
Number of Participants Experiencing a Thromboembolic Event Between the Two Groups
ParticipantsIntravenous Tranexamic AcidOral Tranexamic Acid
Number of Participants Experiencing a Thromboembolic Event Between the Two Groups22

Adverse events

Collected over From day of surgery until 4 week post-operative visit.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Intravenous Tranexamic Acid0/43 (0%)0/43 (0%)2/43 (4.7%)
Oral Tranexamic Acid0/40 (0%)0/40 (0%)2/40 (5%)
Most frequent other events
Most frequent other events
EventIntravenous Tranexamic AcidOral Tranexamic Acid
thromboemolitic event (DVT/PE)Vascular disorders2/432/40

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Intravenous Tranexamic AcidOral Tranexamic AcidTotal
<=18 years000
Between 18 and 65 years434083
>=65 years000
Sex: Female, Male
Sex: Female, Male(Participants)Intravenous Tranexamic AcidOral Tranexamic AcidTotal
Female242549
Male191534
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)Intravenous Tranexamic AcidOral Tranexamic AcidTotal
Count of participants——0
Region of Enrollment
Region of Enrollment(participants)Intravenous Tranexamic AcidOral Tranexamic AcidTotal
United States434083
08

Study locations

1 site
  • Henry Ford Health System
    Detroit, Michigan 48202, United States
09

References and documents

Publications

  • Nadler SB, Hidalgo JH, Bloch T. Prediction of blood volume in normal human adults. Surgery. 1962 Feb;51(2):224-32. No abstract available. PubMed 21936146 ↗
  • Good L, Peterson E, Lisander B. Tranexamic acid decreases external blood loss but not hidden blood loss in total knee replacement. Br J Anaesth. 2003 May;90(5):596-9. doi: 10.1093/bja/aeg111. PubMed 12697586 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2017 to primary completion in Jun 2018, 16 months.

Results were first posted in Nov 2026, 8 years 4 months after primary completion.

Of 24 non-industry phase 4 interventional studies under Blood Loss, Surgical, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 25. This study's 16 months is above that.

Counting every sponsor, half of 24 studies reached it within 12 months; a quarter within 8 and three quarters within 25.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 23, 2017
First posted
Jan 31, 2017
StartActual
Feb 15, 2017
Primary completionActual
Jun 15, 2018
CompletionActual
Jul 16, 2018
Results first posted
Nov 10, 2026
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Nov 10, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedIntraPost-operative blood loss betweenChange in Hemoglobin Level Between the two groupsTwo GroupsTime frame: Day of surgery to 1 day after surgery, up to 7 days → Day of surgery up to 24 hours day after surgery
Nov 10, 2026
Secondary outcomes
3 edited, 2 removed
What changed in the outcomes
  • EditedPost-operative dropChange of Blood Volume in hemoglobin betweenMilliliters Between the two groupsTwo GroupsTime frame: 1 day after surgery until patient is discharged, up to 7 days → 1 day after surgery until 7 days after surgery
  • EditedNumber of units transfused betweenParticipants Transfused Between the two groupsTwo GroupsTime frame: 1 day after surgery until patient is discharged, up to 7 days
  • EditedIncidenceNumber of thromboembolic events betweenParticipants Experiencing a Thromboembolic Event Between the two groupsTwo GroupsTime frame: 1 day after surgery until patient returns for first postoperative visit (through study completion, an average of 4 weeks after surgery) → 1 day after surgery until post operative visit 4 weeks after surgery
  • RemovedPost-operative blood loss between the two groupsTime frame: 1 day after surgery until patient is discharged, up to 7 days
  • RemovedPost-operative drain output between the two groupsTime frame: 1 day after surgery until patient is discharged, up to 7 days
Nov 10, 2026
Show all 1 update
  1. Nov 10, 2026
    Results posted
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedIntraPost-operative blood loss betweenChange in Hemoglobin Level Between the two groupsTwo GroupsTime frame: Day of surgery to 1 day after surgery, up to 7 days → Day of surgery up to 24 hours day after surgery
    Secondary outcomes 3 edited, 2 removed
    What changed in the outcomes
    • EditedPost-operative dropChange of Blood Volume in hemoglobin betweenMilliliters Between the two groupsTwo GroupsTime frame: 1 day after surgery until patient is discharged, up to 7 days → 1 day after surgery until 7 days after surgery
    • EditedNumber of units transfused betweenParticipants Transfused Between the two groupsTwo GroupsTime frame: 1 day after surgery until patient is discharged, up to 7 days
    • EditedIncidenceNumber of thromboembolic events betweenParticipants Experiencing a Thromboembolic Event Between the two groupsTwo GroupsTime frame: 1 day after surgery until patient returns for first postoperative visit (through study completion, an average of 4 weeks after surgery) → 1 day after surgery until post operative visit 4 weeks after surgery
    • RemovedPost-operative blood loss between the two groupsTime frame: 1 day after surgery until patient is discharged, up to 7 days
    • RemovedPost-operative drain output between the two groupsTime frame: 1 day after surgery until patient is discharged, up to 7 days
    + 3 other changes: index terms, verification date and responsible party

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT03037515
Responsible party
Sponsor
First posted
Jan 31, 2017
Start date
Feb 15, 2017
Primary completion
Jun 15, 2018
Completion
Jul 16, 2018
Results posted
Nov 10, 2026
Last update
Nov 10, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tranexamic Acid

Start the discussion